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NK cell degranulation upon co-culture with myeloma cells 
revealed that KIR–ligand-mismatched NK cells degranu-
late more than matched subsets and that HLA-E abrogates 
degranulation of NKG2A+ subsets. Inhibition by HLA-
class I and HLA-E was also observed with IL-2-activated 
NK cells and at low oxygen levels (0.6 %) mimicking 
hypoxic bone marrow niches where myeloma cells prefer-
entially reside. Our study demonstrates that NKG2A-nega-
tive, KIR–ligand-mismatched NK cells are the most potent 
subset for clinical application. We envision that infusion of 
high numbers of this subclass will enhance clinical efficacy.
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Abbreviations
ADCC  Antibody-dependent cellular cytotoxicity
AML  Acute myeloid leukemia
BM  Bone marrow
Fab  Fragment antigen binding
GFP  Green fluorescence protein
GvHD  Graft-versus-host disease
HLA  Human leukocyte antigen
HSCT  Hematopoietic stem cell transplantation
KIR  Killer immunoglobulin-like receptor
MFI  Mean fluorescence intensity
MM  Multiple myeloma
NK  Natural killer
PCL  Plasma cell leukemia
Introduction
Multiple myeloma is caused by expansion of malignant 
plasma cells in the bone marrow (BM) and remains largely 
Abstract Immunotherapy with allogeneic natural killer 
(NK) cells offers therapeutic perspectives for multiple 
myeloma patients. Here, we aimed to refine NK cell ther-
apy by evaluation of the relevance of HLA-class I and 
HLA-E for NK anti-myeloma reactivity. We show that 
HLA-class I was strongly expressed on the surface of 
patient-derived myeloma cells and on myeloma cell lines. 
HLA-E was highly expressed by primary myeloma cells 
but only marginally by cell lines. HLA-Elow expression on 
U266 cells observed in vitro was strongly upregulated after 
in vivo (bone marrow) growth in RAG-2−/−γc−/− mice, 
suggesting that in vitro HLA-E levels poorly predict the 
in vivo situation. Concurrent analysis of inhibitory recep-
tors (KIR2DL1, KIR2DL2/3, KIR3DL1 and NKG2A) and 
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incurable with the current treatment options [1]. Alloge-
neic hematopoietic stem cell transplantation (allo-HSCT) 
performed over HLA-C barriers can provide curative anti-
myeloma responses [2]. However, poor clinical outcomes 
and T cell-mediated graft-versus-host disease (GvHD) are 
major limitations of allo-HSCT for myeloma [3–6]. Infu-
sion of alloreactive natural killer cells (NK) cells could 
be an appealing strategy to improve clinical effectiveness 
since the risk of GvHD is low and there is no need for mye-
loablative conditioning [7, 8].
NK cells are large granular lymphocytes with the poten-
tial to selectively kill malignant cells. The balance between 
tolerance to healthy cells and eradication of virally infected 
or tumor cells is established by a panel of activating and 
inhibitory receptors on the NK cell surface [9]. Activating 
receptors, interacting with “stress-induced flags” on dis-
eased cells, trigger NK cell killing. Inhibitory receptors 
bind to self-molecules such as HLA-class I and HLA-E that 
are expressed by virtually every normal cell and protect 
against unwanted NK cell reactivity. An important class 
of inhibitory receptors, the killer immunoglobulin-like 
receptors (KIRs), interacts with HLA-class I molecules on 
the target cell; KIR2DL1 ligates HLA-C group 2 (Lsy80) 
alleles, KIR2DL2/3 ligates HLA-C group 1 (Asn80) alleles 
and KIR3DL1 interacts with HLA-Bw4 motifs [10, 11]. 
The lectin-like family member NKG2A interacts with 
HLA-E [12].
Upon HLA-mismatched allo-HSCT, donor NK cells 
eliminate tumor cells when the patient lacks HLA epitopes 
from the donor, and donor NK cells express KIRs specific 
for these epitopes (KIR-ligand mismatch) [13]. Landmark 
studies in the haplo-identical HSCT setting showed that 
KIR–ligand-mismatched NK cells exert anti-leukemic 
effects and improve survival of acute myeloid leukemia 
(AML) patients [14, 15]. Also in myeloma, incompatibil-
ity between donor KIRs and patient HLA has been asso-
ciated with a better clinical outcome [2]. Moreover, a first 
clinical trial showed that isolated KIR–ligand-mismatched 
NK cells can be safely administrated to myeloma patients 
though the contribution of NK cells, in addition to the con-
ditioning regime, could not be established in this trial [16]. 
Beneficial effects of KIR–ligand-mismatched NK cell infu-
sion have been observed in other types of cancer as well 
[17–20]. Although these studies are encouraging, optimiza-
tion of the clinical efficacy of transferred NK cells is still 
required.
While there are several reasons why NK cells therapy 
could be a major step forward in immunotherapy of cancer, 
various mechanisms have been described that could reduce 
clinical effectiveness, e.g., decreased expression of acti-
vating receptors [21–23], hypoxia [24], the expression of 
immunosuppressive soluble or surface molecules [25–27] 
or infusion of insufficient numbers of (the right) NK cells 
and HLA-class I expression by myeloma cells [28–30]. 
Genotypic selection of a KIR–ligand-mismatched donor 
seems to be a good strategy to reduce inhibitory effects by 
HLA-class I. However, because NK cells can express one 
or a combination of inhibitory receptors, not all donor NK 
cells will exclusively express KIRs that are mismatched 
with HLA-class I of the patient. Furthermore, of all periph-
eral blood NK cells, 20–80 % expresses NKG2A [31, 32]. 
For clinical-grade expanded NK cells, from either hemat-
opoietic progenitor cells [33], blood-derived NK cells 
[34], or pluripotent stem cells [35], this percentage can be 
higher than 80 %. Because HLA-E is low polymorphic and 
all functional HLA-E alleles can inhibit NK cells through 
NKG2A [36], NKG2A could abolish the overall NK cell 
response against HLA-E-expressing tumors, even in the 
KIR–ligand-mismatched setting. This makes HLA-E clini-
cally highly relevant, but information on HLA-E expres-
sion and its inhibitory potential in myeloma is lacking.
In the present study, aimed to refine the selection process 
for NK cell therapy, we studied the relevance of HLA-class 
I and HLA-E for anti-myeloma reactivity of allogeneic 
NK cells. First, we determined the presence of HLA-class 
I and HLA-E on primary myeloma cells and on myeloma 
cell lines, revealing that primary myeloma cells express 
both HLA-class I and HLA-E. Also, we found major dif-
ferences with myeloma cells cultured in vitro and the same 
cells grown in vivo. Second, we assessed the inhibitory 
potential of HLA-class I and HLA-E on different NK cell 
subsets in a co-culture system that allowed synchronized 
analysis of degranulation of individual NK cells subsets, 
demonstrating the potent inhibitory effects of HLA-class I 
and HLA-E on NK cell alloreactivity. To better predict the 
in vivo response, we performed these assays at ambient and 
clinically relevant low oxygen levels.
Materials and methods
Cell culture incubators
Experiments were performed in ambient 95 % humidified 
air, 21 % O2 incubator (SANYO) containing 5 % CO2. 
Hypoxia experiments were completely performed inside 
0.6 % O2 incubators (Invivo2, 1000 Ruskinn Technology 
Ltd) at 37 °C with 5 % CO2.
Cell lines
Myeloma cell lines [37] and HLA-class I-deficient K562 cell 
line (ATCC) were cultured in RPMI-1640 medium (Gibco) 
supplemented with 10 % fetal calf serum (Integro), 1000 U/
mL penicillin (Gibco) and 100 µg/mL streptomycin (Gibco). 
The LME-1 cell line (received through Dr. R. van Oers, AMC, 
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Amsterdam) was cultured in IMDM medium (Gibco), and 
XG-1 in IMDM medium with (500 pg/ml) IL-6 (Biosource).
Flow cytometric analysis of HLA‑E and HLA‑class I 
expression
Material from myeloma and plasma cell leukemia patients 
was obtained as a waste product from a diagnostic proce-
dure that had been approved by the hospital’s medical ethi-
cal committee. Bone marrow cells were stained for CD38 
(HB7, BD), CD138 (CLB-1D4, Sanquin), cytoplasmic 
kappa light chain (G20-193, BD), cytoplasmic lambda 
light chain (1–555–2, BD), HLA-class I (G46-2.6, BD) or 
HLA-E (3D12, eBioscience). HLA expression was deter-
mined on CD38high cells. All flow cytometry-based assays 
were performed on a BD FACS Canto II. Data were ana-
lyzed with BD FACSDiva v6.1.2 or FlowJo 7.6.
HLA genotyping and NK cell donor selection
Genotypic expression of HLA epitopes (HLA-C1, HLA-
C2 and HLA-Bw4) in cell lines (supplemental table S1) 
and in healthy volunteers was determined by sequence-
specific oligonucleotides (SSO) analysis and Luminex® 
according to the manufacturer’s guidelines (One Lambda). 
Healthy volunteers, with genotype HLA-C1+C2+Bw4+ 
and phenotypically expressing KIR2DL1, KIR2DL2/3 and 
KIR3DL1 were selected as NK cell donors. Donors signed 
informed consent forms.
NK cell isolation and CD107a degranulation assay
NK cells were isolated from blood by negative MACS 
selection (Miltenyi Biotec) according to manufacture’s 
instructions. NK cells were activated with 1000 U/ml IL-2 
(Proleukin) for 6 h at 21 % O2. Activated NK cells were co-
cultured with target cells at 1:1 ratio in 96-well round-bot-
tom plates in duplicate with anti-CD107a-Horizon-V450 
(H4A3, BD). After 1 h, co-culture at 21 % O2 or 0.6 % O2, 
monensin (BD GolgiStop, Cat# 554724) was added. After 
another 8–9 h, co-cultures were stained on ice with anti-
CD3-APC/H7 (SK7, BD), anti-CD56-PeCy7 (B159, BD), 
anti-KIR2DL1-APC (143211, R&D), anti-KIR2DL2/3/
S2-PE (DX27, Miltenyi Biotec), anti-KIR3DL1-FITC 
(DX9, Miltenyi Biotec) and anti-NKG2A-PC5.5 (Z199, 
Beckman Coulter). For co-cultures with IL-2-activated NK 
cells, target cells were pre-incubated for 6 h at 21 % O2 
or 0.6 % O2. For experiments without IL-2 activation, tar-
get cells cultured at 21 % O2 were used. Target cells were 
subsequently co-cultured with freshly isolated NK cells 
in a 10- to 12-h degranulation assay. For HLA-E blocking 
experiments, target cells were pre-incubated for 30 min at 
37 °C with 10 µg/ml of anti-HLA-E (3D12; IgG1 isotype 
eBioscience) or IgG1 isotype control. Gating strategy is 
described in supplemental figure S2.
HLA‑E induction by peptides
U266 cells were incubated with 500 µM of HLA-A1 
(VMAPRTLLL), HLA-B7 (VMAPRTVLL) or a control 
peptide (RGPGRAFVTI) for 12 h at 37 °C. As additional 
negative controls, U266 cells were incubated without pep-
tide or with DMSO, the solvent of the peptides. After 12 h, 
HLA-E expression was determined by flow cytometry. For 
degranulation assays, peptide incubation was done for 2 h 
after which the cells were co-cultured with IL-2-activated 
NK cells in a 12-h degranulation assay.
Mice and multiple myeloma disseminated growth 
model in RAG‑2−/−γc−/− mice
RAG-2−/−γc−/− mice were bred in the SPF unit Cen-
tral Animal Facility of the Utrecht University using filter 
top cages. After a total body irradiation (3.0 Gy 200 kV 
X-rays), the mice received an injection with 5 × 106 cells 
intravenously from the green fluorescence protein (GFP)–
luciferase-marked, human MM cell line U266. Tumor 
growth of the U266-luc cell line was monitored by biolu-
minescence imaging as described previously [37]. Upon 
killing the mice, BM cells were stained for human-CD45, 
HLA-class I and HLA-E.
Statistical analyses
Statistical significances of differences were determined by 
paired t test or two-way repeated measures ANOVA with 
Bonferroni correction. A p value of <0.05 was considered 
significant. Analysis was performed with GraphPad Prism 
V (Graphpad Software Inc).
Results
Primary myeloma cells express HLA‑class I 
and HLA‑E on the cell surface
To study HLA expression on primary myeloma cells, 
cells were obtained from BM aspirates of eight myeloma 
patients and one plasma cell leukemia (PCL) patient. 
Directly upon isolation, surface expression of HLA-class I 
and HLA-E was analyzed by flow cytometry. Plasma cells 
were identified as CD38high and displayed skewed intracel-
lular expression of either kappa or a lambda light chain 
indicative for myeloma (supplemental figure S1). In all 
myeloma patients, CD38high cells were positive for HLA-E 
and HLA-class I (Fig. 1). Also, CD38high cells from the 
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PCL patient expressed HLA-E. The level of HLA-E and 
HLA-class I on CD38high cells was comparable to the 
level observed on normal BM cells of the same patient 
or on plasma cells from a non-myeloma patient (data not 
shown).
Myeloma cell lines express high levels of HLA‑class I 
and heterogeneous levels of HLA‑E
Surface expression of HLA-class I and HLA-E was also 
assessed on a panel of myeloma cell lines including U266, 
L-363, LME-1, UM-9, RPMI-8226/S, OPM-1 and XG-1, 
and on the leukemia cell line K562. This revealed that 
all myeloma cell lines strongly expressed HLA-class I 
(Fig. 2a). K562 cells were almost completely negative for 
HLA-class I. The cell lines differed in expression levels 
of HLA-E; K562 and OPM-1 lacked cell surface HLA-
E, while U266, L-363, UM-9, LME-1 and RPMI-8226/S 
expressed low levels of HLA-E (<1 log difference with the 
isotype control). XG-1 expressed intermediate HLA-E lev-
els (approximately 1 log difference with the isotype con-
trol) (Fig. 2b).
Fig. 1  Patient-derived primary 
myeloma cells express HLA-
class I and HLA-E on the cell 
surface. Mononuclear cells 
obtained from bone mar-
row aspirates of patients with 
myeloma (n = 8) or plasma cell 
leukemia (PCL; n = 1) were 
stained for CD38, HLA-class I 
and HLA-E and were analyzed 
by flow cytometry. a Histo-
grams show HLA-class I or 
HLA-E cell surface expression 
(open histograms) on CD38high 
cells for the myeloma or PCL 
patients. Matched isotype con-
trols are depicted in gray histo-
grams. b Graph shows MFI data 
obtained from the histograms. 
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Fig. 2  Myeloma cell lines express high levels of HLA-class I and 
heterogeneous levels of HLA-E. HLA-class I a and HLA-E b surface 
expression of HLA-class I-deficient K562, and seven myeloma cell 
lines (U266, L-363, LME-1, UM-9, RPMI-8226/S, OPM-1, XG-1) 
was determined by flow cytometry. Histograms are representative of 
three different measurements. HLA expression is depicted by open 
histograms and matched isotype controls by gray histograms
Fig. 3  In vivo grown U266 
myeloma cells have a higher 
HLA-E expression than in vitro 
cultured U266 cells. 5*106 
U266 cells were injected in 
RAG-2−/−γc−/− immunode-
ficient mice. Tumor growth 
was monitored at multiple 
time points after injection 
by bioluminescent imaging. 
Once the human endpoint was 
reached, mice were killed and 
the bone marrow was harvested 
and stained for HLA-class I 
and HLA–E. U266 cells grown 
in vitro were also stained for 
HLA-class I and HLA-E. HLA 
expression was analyzed by 
flow cytometry. Representative 
histograms are shown of HLA 
expression (open histograms) 
and matched isotype controls 
(gray histograms). Numbers 
in the histograms depict MFI 
of the isotype control (gray) 
or HLA (black). Graphs show 
MFIs obtained from  histo-
grams of in vivo HLA expres-
sion. Each dot represents one 
mouse
RAG2-/- c-/-
U266 in vitro 
Day 69 Day 34 
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In vivo grown U266 myeloma cells express higher levels 
of HLA‑E than in vitro grown U266 cells
As we observed a clear expression of HLA-E on all patient-
derived CD38high cells, but only low expression on in vitro 
cultured myeloma cell lines, we compared HLA-E expres-
sion on in vitro grown U266 cells with U266 cells after in 
vivo passaging. To this end, GFP–luciferase-marked U266 
cells were injected in RAG-2−/−γc−/mice, thereby provid-
ing the cells with their natural BM environment. Tumor 
growth was monitored with bioluminescence imaging. At 
end-stage myeloma development, the BM was harvested 
and tumor cells, identified by GFP and human leukocyte 
marker CD45, were analyzed for surface HLA-E and HLA-
class I. This analysis revealed that both in vitro and in vivo 
grown U266 cells strongly expressed HLA-class I, albeit 
that the in vivo level was somewhat lower than the in vitro 
level. A striking observation was that the in vivo passaged 
U266 cells expressed much higher levels of HLA-E when 
compared to U266 cells grown in vitro (Fig. 3).
KIR–ligand‑mismatched NK cell subsets mediate the 
most effective anti‑myeloma response
To evaluate the functional relevance of HLA for NK cell 
anti-myeloma alloreactivity, myeloma cell lines were co-
cultured with NK cells from donors expressing all three 
inhibitory epitopes (i.e., HLA-C1+, HLA-C2+ and HLA-
Bw4+). To enable comparative analysis of anti-myeloma 
activity of NK cell subsets, cells were stained for KIRs 
and NKG2A, and NK cell degranulation of subsets was 
assessed by flow cytometric analysis for the degranula-
tion marker CD107a (supplemental figure S2). Previously, 
we and others showed that CD107a is a reliable surrogate 
marker for NK cell cytotoxicity [24, 38] and traditional 
cytotoxicity assays as such would not allow the analysis of 
subgroups without cell sorting.
To assess the importance of KIR–HLA class I–KIR 
interaction, NKG2A−KIR+ NK cells were classified into 
three subsets based on the target HLA-class I genotype 
(supplemental table S1): a subset exclusively expressing 
matched KIRs, a subset expressing only mismatched KIRs, 
and a subset co-expressing matched and mismatched KIRs. 
For all three subsets, the percentage of CD107a+ cells was 
below 1 % without target cells (Fig. 4a). The percentage of 
degranulating CD107a+ matched NK cells upon culture 
with myeloma cell lines was also low, 5.1 % with OPM-1 
and <2.2 % with the other cell lines. For the mismatched 
subsets, the percentage of degranulating NK cells was 
higher than the percentage of the matched subset. The mag-
nitude differed between the target cell lines: 20.1 % with 
U266, 12.7 % with L-363, 10.3 % with LME-1, 2.9 % with 
UM-9, 2.1 % with RPMI-8226/S and 15.8 % with OPM-1. 
For the NK cell subset co-expressing both matched and 
mismatched KIRs, percentages of CD107a+ cells were in 
between that of the subset exclusively expressing matched 
KIR and the subset exclusively expressing mismatched 
KIR. Together, these data illustrated that anti-myeloma NK 
cell reactivity is abrogated by HLA-class I.
Since clinical NK cell products usually consist of 
cytokine-activated or cytokine-expanded NK cells [16, 39, 
40], we investigated whether our observation that unacti-
vated KIR–ligand-mismatched NK cells are better respond-
ers to myeloma than matched NK cells was also true for 
activated NK cells. To test this, NK cells were activated for 
6 h with IL-2 prior to the analysis of degranulation of the 
different NK cell subsets. Spontaneous degranulation of 
activated NK cells was again low (<0.5 %). For matched 
NK cells, the percentage of CD107a+ cells in response to 
myeloma target cells was 10.6 % with U266, 7.8 % with 
L-363, 6.4 % with RPMI-8226/S and 24 % with OPM-1 
(Fig. 4b). In line with our first observation, NK cells that 
were KIR–ligand mismatched showed a significantly better 
anti-MM response than the matched subsets; the percent-
ages of CD107a+ cells were 54 % with U266, 54.8 % with 
L-363, 32.6 % with RPMI-8226/S and 43.2 % with OPM-1.
Previously, we showed that hypoxia can inhibit the 
cytotoxic capacity of NK cells and that IL-2 activation 
of NK cells can compensate for that [24]. As the mye-
loma microenvironment exhibits hypoxic regions [41], 
Fig. 4  KIR–ligand-mismatched NK cell subsets mediate the most 
effective anti-myeloma response. a Six myeloma cell lines were co-
cultured with NK cells isolated from peripheral blood in the presence 
of anti-CD107a at 21 % of oxygen. After 12 h, cells were stained 
for KIRs and NKG2A and degranulation (CD107a+) was measured 
by flow cytometry. For analysis, NK cells (CD3-CD56+) were sub-
divided into 16 subpopulations based on their expression of different 
inhibitory receptors and the percentage of CD107a+ cells per subset 
was analyzed. Next, the 16 populations were categorized into three 
subgroups: KIR–ligand-matched NK cells (white bars), KIR–ligand-
mismatched NK cells (black bars) and NK cells with a co-expression 
of KIR–ligand-mismatched and matched cells (gray bars). This was 
done per myeloma cell line based on the HLA genotype of the cell 
line. For all subsets, NKG2A+ NK cells were excluded from the anal-
ysis. Graph shows mean percentage and SEM of CD107a+ NK cells 
for each of these subgroups. b Myeloma cell lines were pre-incubated 
for 6 h at 21 % or 0.6 % O2. NK cells were activated for 6 h with 
1000 U/ml IL-2 at 21 % of oxygen. After 6 h, NK cells and myeloma 
cells were co-cultured for an additional 10 h at 21 % or 0.6 % O2. 
Analysis of degranulation of IL-2-activated NK cells subsets was per-
formed as described under a. Graph shows mean percentage and SEM 
of CD107a+ NK cells, for NK cells exclusively expressing matched 
(white bars) or mismatched KIRs (gray bars) at 21 % O2 (open bars) 
or 0.6 % O2 (dashed bars). Unactivated NK cells (c) or activated NK 
cells (d) were co-cultured with K562 as described in a and b. Graphs 
in c and d show mean percentage and SEM of CD107a+ NK cells for 
subsets exclusively expressing KIR2DL1 or KIR2DL2/3 or KIR3DL1. 
Experiments in a and c were performed in the same assay in dupli-
cate cultures for n = 4 healthy donors. Experiments in b and d were 
performed in the same assay in duplicate cultures for n = 5 donors. 
*p < 0.05, **p < 0.01, ***p < 0.001
▸
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we also determined degranulation of IL-2-activated NK 
cell subsets at physiologically relevant hypoxic cul-
ture conditions of 0.6 % O2. In response to all tested 
cell lines and for both matched and mismatched subsets, 
the percentage of CD107a+ cells was comparable to 
the levels observed at 21 % of oxygen. Thus, also under 
hypoxic culture conditions, KIR–ligand-mismatched 
subsets displayed superior anti-myeloma activity 
(Fig. 4b).
As a control, degranulation of KIR2DL1, KIR2DL2/3 or 
KIR3DL1 single positive NK cells in response to the HLA-
class I negative K562 cell line was determined. For the 
unactivated NK cells, this showed that all three subsets had 
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K562 (Fig. 4c). Also for the activated NK cells, there was 
no significant difference in the percentage of CD107a+ 
cells between KIR2DL1, KIR2DL2/3 and KIR3DL1 single 
positive subsets, either at 21 % O2 or at 0.6 % O2 (Fig. 4d), 
demonstrating that all subsets can degranulate to a compa-
rable extent in the absence of inhibitory signaling by KIR-
ligand interaction.
HLA‑E can abrogate the anti‑myeloma response 
of NKG2A+ NK cells
To evaluate the functional relevance of HLA-E, we used 
the experimental setup described above and determined 
degranulation of NK cells expressing only the inhibitory 
receptor for HLA-E, i.e., NKG2A. In the absence of tar-
get cells, 1 % of KIR-NKG2A+ NK cells was positive for 
CD107a (Fig. 5a). Between 16 and 21 % of KIR-NKG2A+ 
NK cells expressed CD107a upon co-culture with U266, 
L-363 and OPM-1. This percentage was only slightly 
lower than the percentage observed with the HLA-negative 
K562, suggesting that the low levels of HLA-E on U266, 
L-363 and OPM-1 were not sufficient to inhibit the KIR-
NKG2A+ NK cells. In response to LME-1, UM-9, RPMI-
8226/S and XG-1, only 2–6 % of the KIR-NKG2A+ NK 
cells was positive for CD107a. To investigate whether the 
poor response against these targets was the consequence 
of HLA-E, despite its low expression (Fig. 2), HLA-E was 
blocked on these four cell lines with an anti-HLA-E anti-
body. For UM-9 or XG-1, blocking did not significantly 
increase NK cell degranulation as compared to the isotype 
control (Fig. 5b). However, for LME-1 or RPMI8226/S, 
blocking enhanced degranulation of KIR-NKG2A+ NK 
subsets of all four donors. This enhanced degranulation 
was not observed in NKG2A−KIR+ subsets (data not 
shown), suggesting that the effect was HLA-E specific. 
Nevertheless, we cannot completely exclude the possibility 
that the HLA-E antibody had triggered antibody-mediated 
cellular cytotoxicity by binding to Fc receptors. Hence, 
although HLA-E is not the only contributing factor, our 
data show that HLA-E can clearly inhibit the anti-myeloma 
response of KIR-NKG2A+ NK cells.
We also studied degranulation of IL-2-activated KIR-
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Fig. 5  HLA-E can abrogate the anti-myeloma response of NKG2A+ 
NK cells. a The tumor cell lines were co-cultured at 21 % O2 with 
freshly isolated peripheral blood-derived NK cells for 12 h, in 
the same assay as in Fig. 4a/c. NK cells expressing only NKG2A 
as an inhibitory receptor were analyzed downstream for CD107a 
expression. Graph shows mean percentage and SEM CD107a+ of 
NKG2A+ KIR− NK cells. b LME-1, UM-9, RPMI-8226/S and 
XG-1 were co-cultured with non-activated NK cells for 12 h at 21 % 
O2, in the presence of an HLA-E-blocking antibody (black bars), an 
IgG1 isotype control (gray bars) or without antibody (white bars). 
Graph shows mean normalized percentage of CD107a+ cells of 
NKG2A+ KIR− NK cells (% with Ab divided by % without anti-
body). c Myeloma cell lines were pre-incubated for 6 h at 21 % or 
0.6 % O2. NK cells were activated with 1000 U/ml IL-2 at 21 % O2. 
Thereafter, they were co-cultured with K562, U266, L363, RPMI-
8226/S and OPM-1 for 10 h at 21 % O2 or at 0.6 % O2, and CD107a 
expression on KIR-NKG2A+ NK cells was analyzed as described 
in Fig. 4. Graph shows mean percentage and SEM CD107a+ of 
NKG2A+ KIR− NK cells. All experiments were performed in dupli-
cate and with n = 5 donors. ***p < 0.001
▸
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L-363, RPMI-8226/S and OPM-1. Spontaneous degranula-
tion without target cells was 5 %. In response to K562, 60 % 
of the KIR-NKG2A+ NK cells expressed CD107a, while 
this was 30–50 % in response to the myeloma cells (Fig. 5c). 
This phenomenon was also valid for targeting myeloma in a 
hypoxic environment of 0.6 % oxygen, showing that degran-
ulation of activated NK cells was not severely hampered by 
the low levels of HLA-E present on the myeloma cell lines.
Upregulation of HLA‑E on myeloma cells diminishes 
degranulation of IL‑2‑activated NKG2A+ NK cells
Most of the cell lines in our panel expressed relatively low 
levels of HLA-E as compared to the levels observed in vivo 
in myeloma patients and in mice, and therefore, we ques-
tioned whether a higher, more clinically relevant level of 
HLA-E expression would inhibit degranulation of activated 
NKG2A+ NK cells. HLA-E expression was enhanced on 
one of the HLA-Elow cell lines (U266) by pre-incubation 
with A1- or B7-peptides. Both peptides are natural binders 
of HLA-E derived from the leader sequence of HLA-A1 or 
HLA-B7 allotypes and have been shown to enhance sur-
face HLA-E levels by stabilization of the molecule on the 
cell surface [12]. Indeed, the incubation with either A1- or 
B7-peptide enhanced the level of HLA-E on U266 as com-
pared to a non-HLA-E binding control peptide or DMSO 
(Fig. 6a). Subsequent co-culture experiments with U266- 
and IL-2-activated allogeneic NK cells revealed that in the 
control conditions (U266 alone, with DMSO or control pep-
tide), 40–50 % of the NK cells expressed CD107a (Fig. 6b). 
In response to U266 pre-incubated with A1- or B7-peptide, 
the percentage of CD107a+ KIR-NKG2A+ NK cells was 
reduced from 40 to 50 % to only 15–20 %. Degranulation 
of KIR+NKG2A− NK cells was not influenced by pre-
incubation of U266 cells with A1- or B7-peptide. These data 
support that the upregulation of HLA-E on myeloma cells 
that are in principle sensitive to NK cell kill, renders these 
cells resistant to NKG2A+ NK cells, indicating that the 
selection of NKG2A-negative NK cells is essential to effi-
ciently eliminate HLA-E positive myeloma cells.
Discussion
Despite the introduction of novel drugs to treat multiple 
myeloma, this disease has remained largely incurable. NK 
cells can be novel immunotherapeutic candidates, and their 
safety has been documented in clinical trials [17]. Exploi-
tation of the full potential of NK cells requires selection 
of NK cell subsets with the highest possibility of trigger-
ing anti-myeloma and identification of the factors impor-
tant for sustaining NK cell activity in vivo. In our quest of 
further refining NK cell therapy, we evaluated the clinical 
relevance of HLA-class I and HLA-E for the anti-myeloma 
response of alloreactive NK cells.
Expression of HLA-E in primary myeloma has not 
been reported, and the present study shows that HLA-E is 
indeed expressed by CD38high cells of myeloma or PCL 
patients. Our data also demonstrate that primary myeloma 
cells remain positive for HLA-class I, which has been 
described before [28–30]. HLA-class I was also strongly 
expressed by all cell lines in our panel. HLA-E expression, 
on the other hand, was lower on cell lines than on primary 
myeloma cells and ranged from completely absent, e.g., on 
OPM-1, to very low on most of the other myeloma lines. 
Low levels of HLA-E on solid tumor cell lines were also 
reported in three previous studies with 30–37 different in 
vitro cultured cell lines per study mainly of solid tumor 
origin [42–44]. The most striking observation in our study 
was that the HLA-E level on U266 cells grown in the BM 
of RAG-2−/−γc−/−mice was considerably higher than the 
level on in vitro cultured U266 and was relatively compa-
rable to the expression levels in myeloma patients. Thus, 
there seems to be a difference between in vitro and in vivo 
expression levels of HLA, which might be the consequence 
of supportive factors present in vivo that are lacking in 
vitro. This observation is highly relevant for the interpreta-
tion of in vitro NK cell studies using HLA-Elow tumor cells 
in general [45] because the in vitro situation might be very 
limiting in predicting the actual situation in cancer patients.
In a co-culture system allowing the synchronized anal-
ysis of degranulation of NK cell subsets, we identified 
HLA-E as a potent inhibitory factor for anti-myeloma reac-
tivity of NK cells expressing the inhibitory NKG2A recep-
tor (Fig. 5). The impact of HLA-E was most pronounced in 
the experiment where blocking of HLA-E enhanced degran-
ulation of KIR-NKG2A+ NK cells and in the experiment 
where HLA-E binding peptides reduced KIR-NKG2A+ 
NK cell degranulation via the upregulation of HLA-E. This 
is consistent with the inhibitory role of HLA-E described 
in AML and ALL [32]. A limitation of this study is lack of 
use of anti-HLA-E fragment associated with antigen bind-
ing (Fab). Therefore, we cannot fully exclude the possibil-
ity that the enhanced degranulation upon HLA-E antibody 
incubation was caused by triggering of ADCC. However, in 
our study, HLA-E blocking did not enhance degranulation 
of KIR+NKG2A− subsets which also express CD16 and 
can mediate ADCC, suggesting that the enhanced degranu-
lation of KIR-NKG2A+ NK subsets did not trigger ADCC 
at global NK cell level. Lack of ADCC triggering by the 
antibody might be explained by the fact that the HLA-E 
antibody was mouse IgG1 isotype, which has been shown 
to poorly bind to human Fc receptors on monocytes [46]. 
Another possible limitation of our study is that we did not 
confirm our results with MM cells from patient samples 
due to the very poor survival capacity of primary MM cells 
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in culture. Nevertheless, because we showed that primary 
MM cells express relatively high levels of HLA-E, it will 
be important to take the inhibitory effects of HLA-E into 
account in the design of future (clinical) studies. Because 
a large fraction of circulating NK cells and the majority of 
NK cells in clinical products are NKG2A+, HLA-E can be 
expected to have major impact on overall NK cell alloreac-
tivity against HLA-E-expressing tumors. HLA-E-mediated 
Fig. 6  Upregulation of HLA-E 
renders NK-sensitive myeloma 
cells resistant to IL-2-activated 
NKG2A+ NK cells. a U266 
cells were incubated for 12 h 
at 37 °C with 500 µM A1- or 
B7- HLA-E binding peptides. 
As control, U266 cells were 
incubated with a control 
(non-binding) peptide, DMSO 
or medium. HLA-E surface 
expression was determined by 
flow cytometry after staining of 
the cells with anti-HLA-E or an 
IgG1 isotype control. Shown is 
a representative histogram with, 
in gray, the isotype control 
staining, in green, the control 
incubations and, in red, the 
conditions with HLA-E binding 
peptides. Graph shows MFI 
values from the histogram. b 
Myeloma cells were pre-incu-
bated with peptides and controls 
as described in A for 2 h. 
Then, IL-2-activated NK cells 
were added and the cells were 
co-cultured for an additional 
12 h. Percentage of CD107a+ 
cells was determined for three 
donors in NKG2A+ KIR− and 
in NKG2A−KIR+ NK cell 
subsets. Graphs depict means of 
duplicate cultures per donor. X 
axis legend is given in the lower 
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tumor resistance might at least partly explain the negative 
clinical trail results obtained so far. Our current data pro-
vide a strong argument to use NKG2A-negative NK cells in 
future clinical trials or develop strategies to abrogate inhi-
bition by HLA-E.
Our findings consequently demonstrated a higher killing 
potential of KIR–ligand-mismatched NK cells as compared 
to their matched counterparts. We used NK cells from 
HLA-C1-, HLA-C2-, HLA-Bw4-positive donors to rule out 
hyporesponsiveness of non-licensed NK cells, and our data 
with K562 demonstrated that all subsets had more or less 
comparable intrinsic capability to kill MM cells. Therefore, 
it seems unlikely that differences between the subsets were 
caused by, for example, variation in the level of activating 
receptors. In addition, we have shown before that activat-
ing receptors (e.g., NKG2D and NCRs) are homogenously 
distributed on CD56+ cells [24]. Previously, bortezomib-
induced downregulation of HLA-class I [47], KIR-block-
ade with IPH2101 [48] and HLA-blockade with W6/32 
[16] have been shown to enhance killing of myeloma cells 
by NK cells. Our data are in agreement with these studies 
and confirm the relevance of HLA-class I in an alternative 
experimental setup. An advantage of our system is that it 
allows the simultaneous analysis of individual subsets, 
which additionally revealed that the anti-myeloma advan-
tage of mismatched NK cells was reduced by co-expression 
of one or more matched KIR. Hence, selection of NK cell 
subsets with exclusively ligand-mismatched KIRs will be 
important to enhance clinical efficacy.
We recently showed that IL-2 activation is required 
for NK cell anti-myeloma responses in clinically relevant 
hypoxic conditions [24]. In addition, we showed in that study 
that expression of HLA-class I, HLA-E and the NKG2D 
ligands MICA/B and ULPB1-2 by MM cells was not influ-
enced by hypoxia [24]. Here, we demonstrate that, even 
though IL-2 activation enhanced degranulation of all NK cell 
subsets, KIR–ligand-mismatched NK cells still mediated a 
more potent anti-myeloma response than matched NK cells. 
Importantly, we did not observe a difference between anti-
myeloma responses at 21 and 0.6 % O2, indicating that for all 
subsets, activation was sufficient to overcome the inhibitory 
effect of hypoxia. Recently, pre-activation of NK cells with 
a combination of IL-12/IL-15/IL-18 proved to be more effi-
cient in enhancing NK cell effector function as compared to 
activation with IL-2 or IL-15 alone [49, 50]. Thus, cytokines 
other than IL-2 might enhance the therapeutic potential of 
alloreactive NK cells even further.
We acknowledge that in our system, HLA-class I and 
HLA-E were not the only factors determining the magni-
tude of the anti-myeloma response, i.e., HLA-E blocking 
did not completely restore degranulation, and in response 
to some cell lines (e.g., UM-9), even fully KIR–ligand-mis-
matched NK cells did not vigorously degranulate (Fig. 4a). 
Previously, the activating receptors NKG2D, NCRs and 
DNAM-1 have shown to be important for NK cell anti-
myeloma activity [28, 29, 51]. Although our study was not 
designed to investigate the role of activating ligands, anal-
ysis of the NKG2D ligands MICA/B and ULPB2 showed 
that most myeloma cell lines in our panel expressed at least 
one of these ligands (supplemental table S2). UM-9, how-
ever, expressed very low levels of all three ligands, which 
might explain the low capacity to activate NK cells. To 
develop effective immunotherapeutic strategies for resistant 
myeloma, synergy between alloreactive NK cells and drugs 
such as lenalidomide and 17-AAG should be evaluated 
because these drugs have been shown to sensitize myeloma 
by enhancing the expression of activating ligands [48, 52].
In summary, our results show that KIR–HLA-class I and 
NKG2A–HLA-E interactions are highly relevant for NK 
cell reactivity against myeloma. For accurate prediction of 
in vitro data to patient’s reality, two relevant in vivo reali-
ties have to be taken into account: (1) In the bone marrow 
myeloma, cells reside under hypoxic conditions and (2) in 
vivo, myeloma cells express both HLA-class I and HLA-E. 
Infusion of a high number of cytokine-activated alloreac-
tive NKG2A-negative, KIR–ligand-mismatched NK cells 
or the use of KIR-blocking antibody (IPH2101) may help 
to improve the efficacy of alloreactive NK cell therapy.
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